What is our current understanding of how differences in sex can affect obesity prevalence, comorbidities, and treatment options? The rates of obesity worldwide have been steadily rising and are ...

UNITED STATES – Pfizer is ending the development of its potential once-daily pill treatment for obesity after venturing into the biggest and most expensive level of clinical testing. The ...

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or ...

That weight loss often leads to other health benefits. Obesity-related medical conditions usually improve with this weight loss, sometimes to the point where medication is no longer needed ...

Diabetes, metabolic syndrome, and obesity have all been linked to testosterone deficiency. Low testosterone isn't known to cause these health problems, and replacing testosterone isn't the cure.

DOWN. ROYALE AND TODD, BACK TO YOU. ALL RIGHT, COREY, THANK YOU SO MUCH. NEW ON SEVEN. CHILDHOOD OBESITY RATES ARE DROPPING IN NEW MEXICO. BUT THEY’RE STILL HIGHER THAN THE NATIONAL AVERAGE.

New Delhi: Despite Mounjaro being priced lower in the Indian market compared to developed countries, viable and affordable anti-obesity medicines for Indian patients may still be about a year ...

TOKYO -- Temperatures and their fluctuations in the surrounding environment around the time conception occurs affect humans' risk of obesity when they become adults, according to a Japanese ...

Medicare coverage for anti-obesity drugs was not finalized, affecting drugs like Wegovy and Zepbound. Covering weight loss drugs may cost $35 billion from 2026–2034, with estimated savings under ...

On Friday, the CMS announced that it was pulling back a CMS decision made late in the Biden administration that would have led to Medicare and Medicaid covering obesity drugs, including the ...

Rhythm Phar­ma­ceu­ti­cals is look­ing to ex­pand the po­ten­tial mar­ket for its rare obe­si­ty treat­ment Im­civree be­yond ge­net­ic dis­or­ders.